Dyno Therapeutics Announces Inaugural 2025 Genetic Agency Technology Conference and Launch of Dyno Frontiers Program to Accelerate Progress in Patient-Empowering Gene Therapies
WATERTOWN, Mass.--(BUSINESS WIRE)-- Dyno Therapeutics, Inc., a genetic technologies company applying AI to enable safe and effective in vivo delivery of genetic medicines, today announced two new initiatives designed to accelerate progress across the gene therapy field: the inaugural Genetic Agency Technology Conference (GATC) and the Dyno Frontiers Program for innovative therapeutic developers. Details were shared during the company's Scientific Symposium at the 28th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting.
'At Dyno, we believe that building the next generation of therapies will require not just new technical innovation, but also collaboration between many stakeholders and a focused effort to thoroughly solve present bottlenecks,' said Eric Kelsic, Ph.D., CEO and Cofounder of Dyno. 'These two new initiatives reflect Dyno's commitment to maximizing our positive impact on patients. We achieve this by partnering and by deepening relationships within a community of gene therapy developers, technical experts and patients, along with their families and patient advocates – all united by the common goal of enabling patients to improve their health with safe and effective genetic medicines.'
The Genetic Agency Technology Conference
Dyno's GATC event is scheduled to take place in Boston, Massachusetts on November 11th, 2025. This one-day interactive gathering will convene leaders from across the gene therapy ecosystem—including technical experts, therapeutic developers, patients, their families and patient advocates—to strengthen a community working to develop cutting-edge technologies and drive progress toward solving unmet patient needs. With GATC, Dyno aims to spark collaboration around the shared goal of genetic agency: giving patients the ability to improve their health at a genetic level through access to next‑generation gene technologies that are safe, effective and widely accessible.
'When developing a new technology, the most important thing is to make something people want. GATC will bring therapeutic developers working at the frontiers of science and technology together with those who care the most about these transformative treatments: patients, their families and patient advocacy organizations. As we team up to overcome the extraordinary challenges required to develop groundbreaking new medicines, we should also recognize the amazing progress that is being made across fields, and look ahead with optimism to a better future for patients that we can build, when leaders across science, technology, and patient advocacy work together,' Kelsic explains. 'By bringing the developers and users of these technologies together, GATC will catalyze collaboration, helping uncover the true nature of present challenges, and generating unexpected insights that will accelerate progress to realize the potential of what genetic medicine can deliver for patients.'
Interested participants can sign up for updates or request an invitation at www.dynotx.com/gatc2025. Further details about the conference will be announced in the coming months.
The Dyno Frontiers Program
Building on Dyno's successful partnerships with leading gene therapy companies, the Dyno Frontiers Program focuses on assisting select gene therapy developers looking to demonstrate the transformative therapeutic potential of their innovative genetic payloads. The program provides technological and scientific support for developers to initiate non-human primate (NHP) studies with clinic-ready genetic payloads for eye, muscle, or central nervous system indications.
Participants in the Frontiers Program will:
Gain access to Dyno's leading-edge AAV capsid delivery vectors to demonstrate the in vivo effectiveness of their innovative clinic-ready genetic payloads in eye, muscle, or central nervous system indications.
Receive scientific advice from Dyno on capsid selection, NHP study design, vector manufacturing, and performance quantification.
Collaborate with Dyno to measure capsid performance across distinct payload modalities.
'As genetic technologies advance and diversify, gene therapy developers increasingly need high-performance delivery vectors to realize the therapeutic potential of their innovative payload strategies,' Kelsic continued. 'We're excited to offer this first-of-its-kind opportunity for innovative gene therapy developers to demonstrate the in vivo effectiveness of their genetic payloads, bringing these transformative drug candidates one critical step closer to the patients who need them most.'
Eligible therapeutic developers seeking to demonstrate the therapeutic potential of their innovative clinic-ready genetic payloads are invited to participate at www.dynotx.com/frontiers-program.
About Dyno Therapeutics
Dyno Therapeutics' mission is to build high-performance genetic technologies that transform patient lives. Dyno is creating better technologies for gene delivery and sequence design to increase 'Genetic Agency'—the capacity for patients to take action and improve their health at a genetic level—enabling individuals to live the life they choose through safe, effective and widely accessible genetic treatments. With frontier AI models and high-throughput in vivo experimentation, Dyno designs optimized AAV delivery vectors that solve gene delivery challenges across a wide range of therapeutic applications. Dyno partners across industries to ensure these life-transforming technologies can help as many patients as possible, including strategic collaborations with leading gene therapy developers Astellas, Roche and Sarepta, and with technology companies including NVIDIA. Visit www.dynotx.com for more information.
Note: The Dyno Frontiers Program is a research initiative and does not imply clinical validation, endorsement, or regulatory approval.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
14 minutes ago
- Business Wire
Deadline Approaching: Fortrea Holdings Inc. (FTRE) Investors Who Lost Money Urged To Contact Law Offices of Howard G. Smith
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith reminds investors of the upcoming August 1, 2025 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Fortrea Holdings Inc. ('Fortrea' or the 'Company') (NASDAQ: FTRE) securities between , inclusive (the 'Class Period'). IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN FORTREA HOLDINGS INC. (FTRE), CONTACT THE LAW OFFICES OF HOWARD G. SMITH TO PARTICIPATE IN THE ONGOING SECURITIES FRAUD LAWSUIT. Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at howardsmith@ by telephone at (215) 638-4847 or visit our website at What Happened? On September 25, 2024, the investment bank Jefferies downgraded Fortrea from buy to hold, citing perceived weaknesses in the Company's business model as a contract research organization ('CRO') amid pressure on biotechnology funding and that the cost savings Fortrea expects to achieve by existing transition services agreements ('TSAs') are 'not as material as one might think.' On this news, Fortrea's stock price fell $2.73, or 12.3%, to close at $19.48 per share on September 25, 2024, thereby injuring investors. Then, on December 6, 2024, Baird Equity Research stated that '[g]iven our ongoing concerns around the sector, [Fortrea's] choppy history post spin, and lack of clarity on the abrupt communications course change, we cannot recommend an actionable investment (buy or sell)[.]' On this news, Fortrea's stock price fell $1.90, or 8.1%, to close at $21.67 per share on December 6, 2024. Then, on March 3, 2025, before the market opened, Fortrea announced financial results for the fourth quarter and full year 2024, revealing the Company had missed its previously announced guidance for revenue and adjusted EBITDA for the full year 2024. The Company's financial results revealed full year adjusted EBITDA of $202.5 million, well below the Company's previously announced guidance of $220 million to $240 million. The Company also revealed full year revenue of $2.696 billion, which missed previously announced guidance of $2.7 billion to $2.725 billion. The Company further revealed financial guidance for the full year 2025, which projected declines in revenue and adjusted EBITDA, with revenues of $2.450 billion to $2.550 billion and adjusted EBITDA in the range of $170 million to $200 million. Thomas Pike ('Pike'), the Company's then-Chief Executive Officer ('CEO'), explained that 'full-service work for projects from the pre-spin period,' 'have less revenue and less profitability' and 'post-spin work is not coming on fast enough to offset the pre-spin contract economics.' Pike further revealed 'this older versus newer mix issue will continue to negatively impact our financial performance during 2025.' On this news, Fortrea shares fell $3.47, or 25.1%, to close at $10.38 per share on March 3, 2025, thereby injuring investors further. What Is The Lawsuit About? The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) Fortrea overestimated the amount of revenue the Pre-Spin Projects were likely to contribute to the Company's 2025 earnings; (2) Fortrea overstated the cost savings it would likely achieve by exiting the TSAs; (3) as a result, the Company's previously announced EBITDA targets for 2025 were inflated; (4) accordingly, the viability of the Company's post-Spin-Off business model, as well as its business and/or financial prospects, were overstated; and (5) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times. If you purchased or otherwise acquired Fortrea securities during the Class Period, you may move the Court no later than August 1, 2025 to ask the Court to appoint you as lead plaintiff if you meet certain legal requirements. Contact Us To Participate or Learn More: If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us: Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020, Telephone: (215) 638-4847 Email: howardsmith@ Visit our website at: To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Business Wire
39 minutes ago
- Business Wire
Deadline Alert: Organon & Co. (OGN) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit
LOS ANGELES--(BUSINESS WIRE)-- Glancy Prongay & Murray LLP reminds investors of the upcoming deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Organon & Co. ('Organon' or the 'Company') (NYSE: OGN) securities between October 31, 2024 to April 30, 2025, inclusive (the 'Class Period'). IF YOU SUFFERED A LOSS ON YOUR ORGANON INVESTMENTS, CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS UNDER THE FEDERAL SECURITIES LAWS. What Happened? On May 1, 2025, Organon released its first quarter 2025 financial results, announcing that management had reset the Company's dividend payout, from $0.28 to $0.02 and would 'redirect those funds to debt reduction.' On this news, Organon's stock price fell $3.48, or 26.9%, to close at $9.45 per share on May 1, 2025, thereby injuring investors. What Is The Lawsuit About? The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) Organon's optimistic reports of the dividend payout as the Company's 'number one priority,' were offset by Organon's newly implemented debt reduction strategy, thus, leading to a drastic decrease – over 70% – of the quarterly dividend; (2) Organon planned to prioritize debt reduction following the Company's acquisition of Dermavant; and (3) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times. If you purchased or otherwise acquired Organon securities during the Class Period, you may move the Court no later than July 22, 2025 to request appointment as lead plaintiff in this putative class action lawsuit. Contact Us To Participate or Learn More: If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us: Charles Linehan, Esq., Glancy Prongay & Murray LLP, 1925 Century Park East, Suite 2100, Los Angeles California 90067 Email: shareholders@ Telephone: 310-201-9150, Toll-Free: 888-773-9224 Visit our website at Follow us for updates on LinkedIn, Twitter, or Facebook. If you inquire by email, please include your mailing address, telephone number and number of shares purchased. To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Business Wire
an hour ago
- Business Wire
Deadline Alert: Red Cat Holdings, Inc. (RCAT) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit
LOS ANGELES--(BUSINESS WIRE)-- Glancy Prongay & Murray LLP reminds investors of the upcoming July 22, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Red Cat Holdings, Inc. ('Red Cat' or the 'Company') (NASDAQ: RCAT) securities between , inclusive (the 'Class Period'). IF YOU SUFFERED A LOSS ON YOUR RED CAT INVESTMENTS, CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS UNDER THE FEDERAL SECURITIES LAWS. What Happened? In March 2022, Red Cat announced that its subsidiary Teal Drones, Inc. ('Teal') had been selected to compete in Tranche 2 of the U.S. Army's Short Range Reconnaissance Program of Record (the 'SRR Program'). On July 27, 2023, Red Cat released its fiscal year 2023 financial results and revealed that its Salt Lake City Facility could only produce 100 drones per month and that construction of the facility was only 'substantially completed' and, while it could potentially reach a production capacity of one thousand drones per month over the next two to three years, it would require additional capital investments. On this news, Red Cat's stock price fell $0.10, or 8.9%, to close at $1.02 per share on July 28, 2023, thereby injuring investors. Then, on September 23, 2024, Red Cat released its first quarter fiscal 2025 financial results, missing consensus estimates and disclosing that it had spent 'the past four months . . . retooling [the Salt Lake City Facility] and preparing for high volume production[,]' while admitting that a 'pause in manufacturing of Teal 2 and building our Army prototypes impacted Teal 2 sales' because it 'couldn't produce and sell Teal 2 units while retooling [its] factory.' On this news, Red Cat's stock price fell $0.80, or 25.3%, over two consecutive trading days to close at $2.36 per share on September 25, 2024. Then, on November 19, 2024, Red Cat announced that it had won the SRR contract, stating that it was worth potentially hundreds of millions of dollars. However, on January 16, 2025, Kerrisdale Capital published a report alleging, among other things, that Red Cat had overstated that value of the SRR Contract and that it was worth approximately $20-25 million, based on U.S. Army budget documents. On this news, Red Cat's stock price fell $2.35, or 21.5%, over two consecutive trading days to close at $8.56 per share on January 17, 2025, thereby injuring investors further. What Is The Lawsuit About? The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) the Salt Lake City Facility's production capacity, and Defendants' progress in developing the same, was overstated; (2) the overall value of the SRR Contract was overstated; and (3) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times. If you purchased or otherwise acquired Red Cat securities during the Class Period, you may move the Court no later than July 22, 2025 to request appointment as lead plaintiff in this putative class action lawsuit. Contact Us To Participate or Learn More: If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us: Charles Linehan, Esq., Glancy Prongay & Murray LLP, 1925 Century Park East, Suite 2100, Los Angeles California 90067 Email: shareholders@ Telephone: 310-201-9150, Toll-Free: 888-773-9224 Visit our website at Follow us for updates on LinkedIn, Twitter, or Facebook. If you inquire by email, please include your mailing address, telephone number and number of shares purchased. To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
